Intensifying systemic therapy improves outcomes in metastatic prostate cancer. As apalutamide and enzalutamide join abiraterone and docetaxel as treatment options for patients, the choice of therapy for individual patients becomes more complex. We anticipate precision targeted and immune therapies will build on the advances of recently completed large-scale trials.
References
Chi, K. N. et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 381, 13–24 (2019).
Davis, I. D. et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N. Engl. J. Med. 381, 121–131 (2019).
Sweeney, C. J. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate vancer. N. Engl. J. Med. 373, 737–746 (2015).
Crawford, E. D. et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med. 321, 419–424 (1989).
Prostate Cancer Trialists’ Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 355, 1491–1498 (2000).
Kyriakopoulos, C. E. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J. Clin. Oncol. 36, 1080–1087 (2018).
Gravis, G. et al. Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies. Eur. Urol. 73, 847–855 (2018).
Fizazi, K. et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 377, 352–360 (2017).
James, N. D. et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N. Engl. J. Med. 377, 338–351 (2017).
Sydes, M. R. et al. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann. Oncol. 29, 1235–1248 (2018).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
T.M.B. has received research funding from Alliance Foundation Trials, Boehringer Ingelheim, Corcept Therapeutics, Endocyte Inc., Janssen Research & Development, Medivation, Inc./Astellas, OncoGenex, Sotio and Theraclone Sciences/OncoResponse, consulting fees from AbbVie, Astellas Pharma, AstraZeneca, Bayer, Boehringer Ingelheim, Clovis Oncology, GlaxoSmithKline, Janssen Biotech, Janssen Japan, Merck and Pfizer and owns stock in Salarius Pharmaceuticals. R.P.K. has received research funding from Merck and Roche.
Additional information
Related links
NCT01957436: https://clinicaltrials.gov/ct2/show/NCT01957436
NCT02799602: https://clinicaltrials.gov/ct2/show/NCT02799602
NCT03678025: https://clinicaltrials.gov/ct2/show/NCT03678025
Rights and permissions
About this article
Cite this article
Kopp, R.P., Beer, T.M. Combining options in metastatic prostate cancer. Nat Rev Urol 16, 569–570 (2019). https://doi.org/10.1038/s41585-019-0217-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-019-0217-z
- Springer Nature Limited